Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Michael J. Mauro, MD, Vivian G. Oehler, MD, James E. Thompson, MD, James K. McCloskey, MD, Michael C. Heinrich, MD, Shaker R. Dakhil, MD, Irene DeGutis, PharmD, David Tabano, PhD, Wasiulla Khan, PhD, Javid J. Moslehi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137613

Published: 2020

Journal Articles

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Ashkan Emadi, MD, PhD, Vu H. Duong, MD, Sandrine Niyongere, MD, Wendy Walinski, Meriem Said, Stephanie Halliwell, Kemji Eke, Kristopher Attwood, PhD, Maria R. Baer, MD, Eunice S. Wang, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141736

Published: 2020

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Abhay Singh, MBBS, MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2019) 134 (Supplement_1): 5095.

https://doi.org/10.1182/blood-2019-132040

Published: 2019

Journal Articles

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Manu Pandey, MBBS, Mahesh Swaminathan, MBBS, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amanda Przespolewski, DO, Swapna Thota, MD, Jeffrey Baron, PharmD, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3866.

https://doi.org/10.1182/blood-2019-132123

Published: 2019

Journal Articles

Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone

Swapna Thota, MD, Abhay Singh, MBBS,MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, Amro Elshoury, MBBChir, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 2645.

https://doi.org/10.1182/blood-2019-131633

Published: 2019

Journal Articles

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Jeffrey Baron, PharmD, Christina L. Lombardi, PharmD, Han Yu, PhD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3501.

https://doi.org/10.1182/blood-2019-131629

Published: 2019

Journal Articles

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Pankit Vachhani, MD, Kyle Wiatrowski, Pragya Srivastava, PhD, Lisa King, Jody Manischewitz, Hana Golding, Heather L Bashaw, BA, Ava R. Dimitroff, Amanda Przespolewski, DO, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD

Blood (2019) 134 (Supplement_1): 4756.

https://doi.org/10.1182/blood-2019-126176

Published: 2019

Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1361.

https://doi.org/10.1182/blood-2019-130582

Published: 2019

Journal Articles

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Mark G. Faber, DO, Amanda Przespolewski, DO, Jeffrey Baron, PharmD, Tara Cronin, BA, Wei Tan, MS, James E. Thompson, MD, Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Swapna Thota, MD

Blood (2018) 132 (Supplement 1): 4366.

https://doi.org/10.1182/blood-2018-99-110846

Published: 2018

Journal Articles

Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Amanda Przespolewski, Chetasi Talati, MD, Pankit Vachhani, MD, Srinivasa Reddy Sanikommu, MD, Swapna Thota, MD, Jeffrey Baron, PharmD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Kendra L. Sweet, MD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 2677.

https://doi.org/10.1182/blood-2018-99-113002

Published: 2018

Journal Articles

Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Swapna Thota, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Elizabeth A. Griffiths, MD, Amanda Przespolewski, DO, James E. Thompson, MD, Teodora Kuzmanovic, Aziz Nazha, Shimoli Vipul Barot, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Sudipto Mukherjee, MDPhDMPH, Meghan Scully, NP, Aaron T. Gerds, MDMS, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Manja Meggendorfer, PhD, Eunice S. Wang, MD, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2018-99-119306

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Intensive Chemotherapy Vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience

Pankit Vachhani, MD, Raed Al Yacoub, MD, Austin Miller, PhD, Tara Cronin, BA, Evelena P. Ontiveros, MD PhD, James E. Thompson, MD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 2620.

https://doi.org/10.1182/blood.V130.Suppl_1.2620.2620

Published: 2017

Journal Articles

Results from the U.S. Life after Stopping TKIs (LAST) Study

Blood (2017) 130 (Supplement 1): 2903.

https://doi.org/10.1182/blood.V130.Suppl_1.2903.2903

Published: 2017

Journal Articles

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

Pankit Vachhani, MD, Craig Freyer, PharmD, BCOP, Jeffrey Baron, PharmD, BCOP, Austin Miller, PhD, Meir Wetzler, MD, James E. Thompson, MD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 5052.

https://doi.org/10.1182/blood.V130.Suppl_1.5052.5052

Published: 2017

Journal Articles

CLAG±M (cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone) Results in High Response Rates in Older Patients with Secondary and Relapsed/Refractory Acute Myeloid Leukemia - a Single Institute Experience

Monica Reddy Muppidi, MD, Craig W. Freyer, PharmD, Laurie Ann Ford, Evelena P Ontiveros, MD PhD, James E. Thompson, MD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2015) 126 (23): 1341.

https://doi.org/10.1182/blood.V126.23.1341.1341

Published: 2015

Journal Articles

Decitabine and Sorafenib Therapy in Patients with FLT3-ITD Mutant Acute Myeloid Leukemia Is Associated with High Response Rates—a Single Institute Experience

Monica Reddy Muppidi, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Craig W Freyer, Pharm.D., BCOP, Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2014) 124 (21): 5284.

https://doi.org/10.1182/blood.V124.21.5284.5284

Published: 2014

Journal Articles

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Elizabeth A. Griffiths, MD, William Brady, Wei Tan, Carlos E Vigil, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Noelle M Dickey, BS, Jill Sperrazza, BS, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2014) 124 (21): 2318.

https://doi.org/10.1182/blood.V124.21.2318.2318

Published: 2014

Journal Articles

Comparison Of Epigenetic Versus Intensive Chemotherapy For Newly Diagnosed Acute Myeloid Leukemia Patients ≥60 Years Old: The Roswell Park Experience

Neha Gupta, MD, Shipra Gandhi, MD, Austin Miller, PhD, Laurie A Ford, BS, CCRC, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2013) 122 (21): 1445.

https://doi.org/10.1182/blood.V122.21.1445.1445

Published: 2013

NARROW

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Intensive Chemotherapy Vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience

Results from the U.S. Life after Stopping TKIs (LAST) Study

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

CLAG±M (cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone) Results in High Response Rates in Older Patients with Secondary and Relapsed/Refractory Acute Myeloid Leukemia - a Single Institute Experience

Decitabine and Sorafenib Therapy in Patients with FLT3-ITD Mutant Acute Myeloid Leukemia Is Associated with High Response Rates—a Single Institute Experience

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Comparison Of Epigenetic Versus Intensive Chemotherapy For Newly Diagnosed Acute Myeloid Leukemia Patients ≥60 Years Old: The Roswell Park Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only